BOSTON and LONDON, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, will be presenting new registrational data from multiple programs at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2019 in Orlando, FL.
On Sunday, December 8, 2019, investigators will describe ongoing clinical progress for two lead development programs in the companys primary immune deficiencies portfolio: OTL-103, an investigational gene therapy in development for the treatment of Wiskott-Aldrich syndrome (WAS) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy; and OTL-101, an investigational gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID).
In addition, on Monday, December 9, 2019, investigators will deliver an oral presentation featuring updated data from the ongoing clinical proof-of-concept study of OTL-203, an investigational gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I) at SR-Tiget.
To learn more about Orchards approach to ex vivo, autologous, hematopoietic stem cell (HSC) based gene therapy, conference attendees can visit booth #2228 in the Exhibition Hall.
Full presentation details are below:
Poster Presentation Details
Lentiviral Hematopoietic Stem and Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome (WAS): Up to 8 Years of Follow up in 17 Subjects Treated Since 2010Publication Number: 3346Session: 801. Gene Therapy and Transfer: Poster IIDate and time: Sunday, December 8, 6:00-8:00pm ET
Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded CohortPublication Number: 3345Session: 801. Gene Therapy and Transfer: Poster IIDate and time: Sunday, December 8, 6:00-8:00pm ET
Oral Presentation Details
Extensive Metabolic Correction of Hurler Disease by Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II TrialPublication Number: 607Session: 801. Gene Therapy and Transfer: Gene Therapies for Non-Malignant DisordersDate and time: Monday, December 9, 7:00am ET
About ADA-SCID and OTL-101Severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID) is a rare, life-threatening, inherited disease of the immune system caused by mutations in the ADA gene resulting in a lack of, or minimal, immune system development.1-4 The first symptoms of ADA-SCID typically manifest during infancy with recurrent severe bacterial, viral and fungal infections and overall failure to thrive, and without treatment the condition can be fatal within the first two years of life. The incidence of ADA-SCID is currently estimated to be one in 500,000 live births in the United States and between one in 200,000 and one in 1 million in Europe.3 OTL-101 is an autologous, ex vivo, hematopoietic stem cell-based gene therapy for the treatment of patients diagnosed with ADA-SCID being investigated in multiple clinical trials in the United States and Europe, including a registrational trial at the University of California, Los Angeles (UCLA). OTL-101 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of ADA-SCID, and Breakthrough Therapy Designation from the FDA.
About WAS and OTL-103Wiskott-Aldrich Syndrome (WAS) is a life-threatening inherited immune disorder characterized by autoimmunity and abnormal platelet function and manifests with recurrent, severe infections and severe bleeding episodes, which are the leading causes of death in this disease. Without treatment, the median survival for WAS patients is 14 years of age. Treatment with stem cell transplant carries significant risk of mortality and morbidities. OTL-103 is an ex vivo, autologous, hematopoietic stem cell-based gene therapy developed for the treatment of WAS that Orchard acquired from GSK in April 2018 and has been developed at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. The global incidence of WAS is estimated to be about 100-260 births per year, with a global prevalence of 2,900-4,700 patients.
About MPS-I and OTL-203Mucopolysaccharidosis type I (MPS-I) is a rare inherited neurometabolic disease caused by a deficiency of the IDUA (alpha-L-iduronidase) lysosomal enzyme required to break down glycosaminoglycans (also known as GAGs or mucopolysaccharides). The accumulation of GAGs across multiple organ systems results in the symptoms of MPS-I including neurocognitive impairment, skeletal deformity, loss of vision and hearing, hydrocephalus, and cardiovascular and pulmonary complications. MPS-I occurs at an overall estimated frequency of one in every 100,000 live births.5 There are three subtypes of MPS-I; approximately 60 percent of MPS-I patients have the severe Hurler subtype and, when untreated, these patients rarely live past the age of 10.Id Treatment options for MPS-I include hematopoietic stem cell transplant and chronic enzyme replacement therapy, both of which have significant limitations. Though early intervention with enzyme replacement therapy has been shown to delay or prevent some clinical features of the condition, it has only limited efficacy on neurological symptoms. OTL-203 is an ex vivo, autologous, hematopoietic stem cell-based gene therapy being studied for the treatment of MPS-I. Orchard was granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the gene therapy program for the treatment of MPS-I developed by the San Raffaele-Telethon Institute for Gene Therapy in Milan, Italy.
About Orchard Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.
Orchards portfolio of ex vivo, autologous, hematopoietic stem cell (HSC) based gene therapies includes Strimvelis, a gammaretroviral vector-based gene therapy and the first such treatment approved by the European Medicines Agency for severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID). Additional programs for neurometabolic disorders, primary immune deficiencies and hemoglobinopathies are all based on lentiviral vector-based gene modification of autologous HSCs and include three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD), transfusion-dependent beta-thalassemia (TDT) and mucopolysaccharidosis type I (MPS-I), as well as an extensive preclinical pipeline. Strimvelis, as well as the programs in MLD, WAS and TDT were acquired by Orchard from GSK in April 2018 and originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy initiated in 2010.
Orchard currently has offices in the UK and the U.S., including London, San Francisco and Boston.
Forward-Looking StatementsThis press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as anticipates, believes, expects, intends, projects, and future or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release, Orchards expectations regarding the timing of regulatory submissions for approval of its product candidates, including the product candidate or candidates referred to in this release, the timing of announcement of clinical data for its product candidates and the likelihood that such data will be positive and support further clinical development and regulatory approval of these product candidates, including any cryopreserved formulations of such product candidates, and the likelihood of approval of such product candidates by the applicable regulatory authorities. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, without limitation: the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be successfully developed or commercialized, the risk of cessation or delay of any of Orchards ongoing or planned clinical trials, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates, the delay of any of Orchards regulatory submissions, the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates, the receipt of restricted marketing approvals, and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.
Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards annual report on Form 20-F for the year ended December 31, 2018 as filed with the U.S. Securities and Exchange Commission (SEC) on March 22, 2019, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
1Orphanet. SCID due to ADA deficiency. 2Whitmore KV, Gaspar HB. Front Immunol. 2016;7:314. 3Kwan A, et al. JAMA. 2014;312:729-738. 4Sauer AV, et al. Front Immunol. 2012;3:265. 5Beck et al. The Natural History of MPS I: Global Perspectives from the MPS I Registry. Genetics in Medicine 2014, 16(10), 759.
Contacts
InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com
MediaMolly CameronManager, Corporate Communications+1 978-339-3378media@orchard-tx.com
- Congress Gives Stem Cells Another Shot -ASK THE EXPERT- ... [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Stem Cell Game 3- Grow with the Flow [Last Updated On: August 5th, 2011] [Originally Added On: August 5th, 2011]
- PROSTATE CANCER and stem cells [Last Updated On: August 13th, 2011] [Originally Added On: August 13th, 2011]
- Preview: 21st Century Snake Oil [Last Updated On: September 2nd, 2011] [Originally Added On: September 2nd, 2011]
- Stem cells: the future of medicine? [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Stem Cells: Politics vs. Medicine [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Mesenchymal Stem Cells in Regenerative Medicine: Of Hopes and Challenges [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- An amazing story of stem cells, regenerative medicine and healing power: [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Preserving Stem Cells: Regenerative Medicine [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- TEDxPhoenix - Jane Maienschein - Stem Cells, Regenerative Medicine and Us [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Personalized Medicine: Stem Cells 1/2 [Last Updated On: September 14th, 2011] [Originally Added On: September 14th, 2011]
- A Century of Stem Cells - Johns Hopkins Medicine [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- What are stem cells? How can they be used for medical benefit? [Last Updated On: September 17th, 2011] [Originally Added On: September 17th, 2011]
- STEM CELLS TRANSLATIONAL MEDICINE Official Announcement [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Turning Adult Stem Cells into Medicine - Zannos Grekos, MD [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- A New Era in Regenerative Medicine [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Bruce Conklin: Drug screening with stem cells [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- Professors Chandran and ffrench-constant - Are stem cells the future of regenerative medicine? [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- Hormone Myths vs. Medical Literature and How to Grow Your Own Stem Cells - Ronald Rothenberg, MD [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Cardiovascular Derivatives of Embryonic Stem Cells in Cardiac Repair and Drug Discovery [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Jackson Laboratory symposium: What's vital for effective stem cell therapies? [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Alzheimer's Disease: Spotlight on Stem Cell Research - Rod Shankle [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- "StemEnhance" the Biggest Scientific [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem cell medical breakthrough? [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- The Future of Stem Cells and Regenerative Medicine [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem Cell Clinical Trials : University of Miami Miller School of Medicine [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Medical tourism in Croatia - Regenerative medicine-Stem cells in reconstructive surgery [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Bioethics Stem Cells and the New Biology [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- Stem Cells: The Hope The Hype and the Science [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- Skin Stem Cells: Their Biology [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Spotlight on Cancer Stem Cell Research [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Sickle Cell Anemia: Stem Cell Gene Therapy - Donald Kohn [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stem Cells and Parkinson's Disease [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stem Cell Research: Macular Degeneration [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- An amazing story of stem cells and regenerative medicine [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stem Cell City - Lisa Ray [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stem Cell Therapy: Healing Force of the future [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Adult Stem Cells in Drug Discovery and Therapeutics [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Medical Breakthrough: First Stem Cell Procedure [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Dr. Judith Oppenheim, Chicago on Dental Stem Cells on WGN-TV's Medical Watch. [Last Updated On: October 9th, 2011] [Originally Added On: October 9th, 2011]
- Jerome Zack: Creating iPS Cells - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Sight for sore eyes - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- Regenerative Medicine Update: Stem Cells and Functional Testing - Mitchell J. Ghen, DO, PhD - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- Stem cells as the future of medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- Neural Stem Cells Reverse Alzheimer's-Like Symptoms - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- Deafness: Spotlight on Stem Cell Research - Ebenezer Yamoah - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Leukemia: Spotlight on Stem Cell Research - Patient Stories - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Epidermolysis Bullosa: Corrected iPS Stem Cell-Based Therapy - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- iPS Stem Cell-Based Treatment of Epidermolysis Bullosa - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Arnold Kriegstein - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Closing Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 23rd, 2011] [Originally Added On: October 23rd, 2011]
- The Sue and Bill Gross Stem Cell Regenerative Medicine Center at UCI - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- Stem Cell Institute - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- StemCellTV Special Report - Stem Cell Therapy a "Medical Game Changer" - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- Adult Stem Cells and Regeneration - Video [Last Updated On: November 8th, 2011] [Originally Added On: November 8th, 2011]
- Cloned Embryonic Stem Cells, FIRST (Brainstorm Ep26) - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Beating Heart Stem Cells - Video [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- Stem Cell Research In Toronto - Video [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- Stem Cells and Their Amazing Potential 2011 trailer - Video [Last Updated On: November 15th, 2011] [Originally Added On: November 15th, 2011]
- Stemcell Research and Aging - Panel 1 - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- Austin Forum - Nov 1st (Part 4 of 4) - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- Vet-Stem Medistem Cellmedicine Rheumatoid Arthritis Stem Cell Video - Video [Last Updated On: December 19th, 2011] [Originally Added On: December 19th, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 26th, 2011] [Originally Added On: December 26th, 2011]
- Stem Cell-Derived Heart Cells: Bruce Conklin - CIRM Science Writer's Seminar - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Pope gives support to adult stem cells and asks for ethics in scientific research - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Stem Cell Treatment for Rheumatoid Arthritis - Darnell Morris - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Personalized Medicine: Stem Cells 2/2 - Video [Last Updated On: January 13th, 2012] [Originally Added On: January 13th, 2012]
- Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening - Webinar Presentation - Video [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- Stem Cell Stage Bypassed in Skin Cell to Brain Cell Transformation [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- Encouraging Results with Stem Cell Transplant for Brain Injury [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- Stem cell injection successfully treats urinary incontinence [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]
- ImmunoCellular Therapeutics To Present at Targeting Stem Cells Symposium during 19th Annual Molecular Medicine Tri ... [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- Adult Stem Cell Success Stories - Barry Goudy - Video [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Stem Cell Treatment for T-6 Spinal Cord Injury - Video [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Stem Cells China-Switzerland.wmv - Video [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Stem cell find offers hope for infertility [Last Updated On: February 27th, 2012] [Originally Added On: February 27th, 2012]
- Stem cell fertility treatments could be risky for older women [Last Updated On: February 28th, 2012] [Originally Added On: February 28th, 2012]
- A*STAR Scientists Make Groundbreaking Discovery on Stem Cell Regulation [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- UGA study reveals basic molecular 'wiring' of stem cells [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]